Source: Joe Martino
- The Facts:Multiple clinical trials for COVID-19 vaccines have shown severe reactions within 10 days after taking the vaccine.
- Reflect On:Should we think twice about taking a rushed vaccine? Is it even necessary given the remarkably low death rate?
What Happened: COVID-19 vaccines have been in production for several months now, and clinical trials have been underway in various countries. One experimental vaccine being developed by CanSino Biologics, Inc. of Tianjin, China, has completed phase 1 of human clinical trials for COVID-19 vaccine (adenovirus type-5 Ad5-nCoV) and involved 108 volunteers, ranging in age from 45–60 years old. advertisement – learn more
Participants were given various levels of dosing, from low to high. 87 (or 81%) of the 108 participants experienced at least one adverse reaction within seven days after receiving the vaccination. Of the 87 who had reactions, 30 were in the low dose group, 30 were in the middle dose group, and 27 were in the high dose group. Overall, 10 of the participants (just under 10%) experienced Grade 3 adverse reactions, most were in the high dose group.
According to researchers conducting the study on the Phase 1 clinical trial for the Ad5-nCoV vaccine:
The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients. Pain was reported in 17 (47%) participants in the low dose group, 20 (56%) participants in the middle dose group, and 21 (58%) participants in the high dose group. The most commonly reported systematic adverse reactions overall were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]). Fever was reported in 15 (42%) participants in the low dose group, 15 (42%) participants in the middle dose group, and 20 (56%) participants in the high dose group. Headache was reported in 14 (39%) participants in the low dose group, 11 (31%) participants in the middle dose group, and 17 (47%) participants in the high dose group. Muscle pain was reported in seven (19%) participants in the low dose group, three (8%) participants in the middle dose group, and eight (22%) participants in the high dose group.
The U.S. Department of Health and Human Services (HHS) describes a Grade 3 adverse event as “severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care” such as “bathing, dressing and undressing, feeding self, using the toilet, taking medications.”
CanSino’s Ad5-n-CoV vaccine uses a chimpanzee adenovirus vector that uses the HEK293 cell lines derived from the tissue of an aborted fetus. The HEK293 human fetal cell line, which was designed, developed and is licensed by Canada’s National Research Council (NRC), is also being used to produce the AZD1222 COVID-19 vaccine developed by the University of Oxford’s Jenner Institute. advertisement –